Table 1.

Characteristics of confirmed (by sequencing) or possible (linked to a confirmed case) cases of infection by BA.4/BA.5 and comparison with BA.1 cases.

Characteristics	BA.4/BA.5		BA.1		p–value a
	(N = 301)		(N = 469)
	n	%	n	%
Sex					NS
F	174	58.2	196	54.7
M	125	41.8	162	45.3
Age					<0.001
0–9	16	5.5	11	2.5
10–19	23	7.9	39	8.8
20–29	32	11.0	112	25.1
30–39	44	15.1	109	24.4
40–49	45	15.5	69	15.5
50–59	61	21.0	65	14.6
60–69	25	8.6	29	6.5
70–79	23	7.9	9	2.0
80 and over	22	7.6	3	0.7
Symptoms					0.002
Asymptomatic	9	3.0	46	10.9
Symptomatic	290	97.0	376	89.1
Duration of symptoms					0.002
7 days or less	173	65.0	114	80.3
More than 7 days	93	35.0	28	19.7
Hospitalization					NS
No	278	95.9	287	97.6
Yes	12	4.1	7	2.4
Intensive care					n/a
No	290	100	292	100
Yes	0	0	0	0
Previous Sars–CoV−2 infections					NS
No	248	95.5	240	86.0
Yes	42	14.5	39	14.0
Risk factors					0.001
No	215	72.9	239	84.2
Yes	80	27.1	45	15.8
Vaccination status					<0.001
Unvaccinated	61	20.9	74	19.6
One dose	4	1.4	20	5.3
Two doses	112	38.3	261	69.2
Three doses	115	39.4	22	5.9
Travel					0.012
No	216	72.7	259	63.5
Yes	81	27.3	149	36.5
Cluster					<0.001
No	139	47.6	202	68.0
Yes	153	52.4	95	32.0

^aPearson's Chi–squared test.

n/a, not applicable; NS, not significant.

Proportions for each variable were calculated per available information (excluding missing data).